# 2024 Prevent |
Prevent addresses the critical issue of pre-eclampsia, a leading cause of maternal and neonatal mortality, by introducing an innovative early screening test. Unlike traditional methods, the test identifies high-risk women between 11 and 16 weeks of pregnancy, allowing for early intervention. By detecting risk early, expectant mothers can receive preventive care, such as low-dose aspirin, well before symptoms develop. This proactive approach aims to improve outcomes and reduce the overall impact of pre-eclampsia
Nanyang Technological University
Targeted antimicrobial treatment for resistant infections